Comparison of the outcomes of hepatocellular carcinoma after hepatectomy between two regional medical centers in China and Japan

• Main Authors: Kai Wang, Susumu Eguchi, Masaaki Hidaka, Tao Jin, Akihiko Soyama, Tamotsu Kuroki, Mingwen Huang, Linquan Wu, Shubing Zou, Jianghua Shao
• Format: Article
• Language: English
• Published: Elsevier 2017-09-01
• Series: Asian Journal of Surgery
• Subjects: China; comparison; hepatectomy; hepatocellular carcinoma; Japan
• Online Access: http://www.sciencedirect.com/science/article/pii/S1015958416300318

Background: Hepatocellular carcinoma (HCC) is a common malignant disease of the liver in China and Japan. The purpose of this study was to compare the outcomes of HCC patients after hepatectomy between two regional medical centers in China and Japan. Methods: Data on HCC after hepatectomy were collected from January 2005 to December 2014 from Nagasaki University Hospital in Nagasaki, Japan and the Second Affiliated Hospital of Nanchang University in Nanchang, China. The patient and tumor characteristics, HCC etiology, and overall survival rates after hepatectomy were investigated. Results: Two hundred patients in the Nagasaki group and 238 patients in the Nanchang group were diagnosed with HCC and underwent hepatectomy. The major underlying liver diseases were hepatitis C infection (32%, 64/200) and nonalcoholic steatohepatitis (NASH) (34.5%, 69/200) in the Nagasaki group, while in the Nanchang group, hepatitis B infection (79.4%, 189/238) was the dominant etiology. Large tumors (> 5 cm), the presence of a tumor capsule and a high alpha-fetoprotein value (≥ 400 U/L) were more frequently observed in the Nanchang group as compared with the Nagasaki group (p < 0.05). According to an outcome analysis, the Nanchang patients showed worse survival rates as compared with Nagasaki patients, particularly those with American Joint Committee on Cancer stages I and III due to the aggressive character of HCC in the Nanchang group. Conclusion: There are significant differences in the clinicopathologic features and outcomes of HCC patients from Japan and China. These differences may impact the eligibility for potentially curative therapy and the prognosis of patients with HCC.